Dr. Pal on the Sequencing of Immunotherapy for Urothelial Carcinoma

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope, discusses the sequencing of immunotherapy regimens in patients with urothelial carcinoma.

There are many drugs approved for patients with metastatic urothelial cancer. The highest levels of evidence are with pembrolizumab (Keytruda) and atezolizumab (Tecentriq) based on phase III data to support both regimens. Determining the sequencing of these agents remains a challenge to be investigated, according to Pal.